Today is April 11, 2026. That makes it World Parkinson's Day — as it is every April 11.
The date is not arbitrary. James Parkinson was born on April 11, 1755, in London. He was a physician, apothecary, and political activist who, in 1817, published a 44-page paper titled "An Essay on the Shaking Palsy." In it, he described a condition he had observed in six patients — a "trembling limb attended with a propensity to bend the trunk forward, and to pass from a walking to a running pace." He had no name for it. He just described what he saw.
Two centuries later, the condition bears his name. It affects over 10 million people worldwide — and that number is growing faster than any other neurological disease on the planet.
What Parkinson's Actually Is
Parkinson's disease is caused by the gradual loss of nerve cells in the substantia nigra — a small, curved area deep in the brainstem. These nerve cells produce dopamine, a chemical that helps coordinate smooth, controlled movement. As they die, dopamine levels drop, and movement becomes increasingly difficult to control.
The most visible symptoms are a resting tremor (shaking at rest, usually starting in one hand), bradykinesia (slowness of movement), and rigidity (stiffness). About 75 to 90 percent of patients experience rigidity. Many describe early symptoms not as tremors but as vague "weakness" or "tiredness" or "incoordination" — making early diagnosis notoriously difficult.
But Parkinson's is not just a movement disorder. It also causes loss of smell (often one of the earliest signs), constipation, overactive bladder, sleep disruption, anxiety, depression, and in later stages, cognitive changes and dementia. Managing the full picture of Parkinson's requires far more than controlling tremors.
Men are approximately 1.5 times more likely than women to develop Parkinson's. While it is most commonly associated with people over 60, roughly 4 percent of diagnoses happen before age 50. This is called Young-Onset Parkinson's. Michael J. Fox, diagnosed at 29, is the most well-known example.
There is no single diagnostic test. Diagnosis is clinical — based on neurological examination, medical history, and in some cases brain imaging. There is also, currently, no cure.
The History of World Parkinson's Day
The first World Parkinson's Day was held on April 11, 1997, established by the European Parkinson's Disease Association with co-sponsorship from the World Health Organisation. It began as a European observance and has since grown to involve organisations in over 80 countries.
The red tulip became the global symbol of Parkinson's awareness in 2005, at the 9th World Parkinson's Disease Day Conference. A Dutch horticulturist named J.W.S. Van der Wereld — who had Parkinson's himself — had cultivated a tulip variety in the 1980s and named it "Dr James Parkinson." It has since become the emblem of hope and solidarity.
The 2026 Theme: Bridge the Care Gap
The theme for World Parkinson's Day 2026 is "Bridge the Care Gap." It reflects a challenge that persists even as medical research advances: many people living with Parkinson's do not have consistent access to specialist care, rehabilitation, mental health support, or the information they need to manage a progressive condition.
Parkinson's Europe, which co-founded World Parkinson's Day, is demanding that European healthcare systems provide three things as a baseline: proactive information for newly diagnosed patients about the support they are entitled to; access to a Parkinson's specialist nurse for every patient; and healthcare systems that are responsive to the changing needs of a condition that progresses over decades.
In India specifically, access to movement disorder specialists — the neurologists with deep expertise in Parkinson's — is severely limited outside major urban centres. Most patients in smaller cities and rural areas rely on general neurologists or internists, if they have access to a specialist at all.
What Science Knows — and Is Still Working On
Treatment for Parkinson's has been dominated for decades by levodopa (L-dopa), a drug that converts to dopamine in the brain and significantly reduces motor symptoms. It was introduced in the late 1960s and remains the most effective symptomatic treatment available. However, its effectiveness diminishes over time, and long-term use causes complications including involuntary movements called dyskinesias.
Deep Brain Stimulation — a surgical procedure that implants electrodes in specific brain regions to modulate neural activity — is available for patients who no longer respond adequately to medication. It can significantly improve quality of life, but it is not curative and not accessible to most patients in lower-income countries.
The research frontier is focused on disease modification — stopping or slowing the underlying neurodegeneration, not just managing symptoms. Several promising approaches are in various stages of development.
Roche and Genentech are advancing prasinezumab, an antibody targeting alpha-synuclein — the protein that abnormally accumulates in the brains of Parkinson's patients. It is now in Phase III trials under the PARAISO trial name, targeting 900 participants across 18 sites over at least two years.
Bayer's subsidiary BlueRock Therapeutics has developed bemdaneprocel — a stem cell-derived dopamine neuron replacement therapy — now in Phase III trials. The goal is to literally replace the neurons that Parkinson's destroys.
Arrowhead Pharmaceuticals, in partnership with Novartis, is working on ARO-SNCA — an RNA-based therapeutic designed to reduce alpha-synuclein production in the brain at the genetic level.
On diagnostics, researchers at the AD/PD 2026 conference in Copenhagen this year presented progress on "seed amplification assays" — tests that can identify Parkinson's pathology in cerebrospinal fluid, skin biopsies, and even tear fluid before symptoms appear. This is the holy grail of early detection: diagnosing Parkinson's at the pre-symptomatic stage so that future disease-modifying treatments can be deployed before significant damage occurs.
The World Parkinson's Coalition, which unites 80+ organisations globally, is also pointing to a concerning trend: since the COVID-19 pandemic, referrals for Parkinson's diagnosis have fallen despite evidence of rapidly rising prevalence. The disease is becoming more common faster than the healthcare systems are adapting.
By 2050, researchers project that 25 million people will be living with Parkinson's — driven primarily by an ageing global population.
What You Can Do Today
The red tulip is the symbol. Wearing it, sharing it, or displaying it on social media today is one way to signal solidarity with the 10 million people currently living with Parkinson's worldwide.
Parkinson's UK has launched a special orange bouquet (orange being the UK chapter's signature colour) available until April 30, with all profits going to research and support services.
For Indian readers: the Movement Disorder Society of India and several hospital-based support groups hold events and awareness walks around World Parkinson's Day. If you know someone showing early signs — tremor at rest, a shuffling gait, a dramatic change in handwriting, or loss of smell — this is a good day to encourage them to seek a neurological evaluation. Early diagnosis, even without a cure, opens access to treatments, support systems, and clinical trials that can make a significant difference.